COVIFENZ | World’s First Plant-Based COVID-19 Vaccine

https://www.istockphoto.com/photos/solarseven

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). 

This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 to 64 years of age.

Subscribe our Twitter Channel to get all updates: Join Now!

To Get All Updates from helpBIOTECH, Subscribe Now by Email

Post a Comment

0 Comments